Having trouble accessing articles? Reset your cache.

Where innovators see room for improvement in China's Drug Administration Law

The innovative drug industry sees room for improvement and clarification in China's Drug Administration Law, which excluded IP reforms such as patent linkage and data exclusivity.

China's National People's Congress (NPC) passed the revised Drug Administration Law (DAL), the first major revision of China's drug statutes in 18 years, on Monday, codifying several key policy reforms and increasing penalties for manufacturing counterfeit or substandard drugs (see "China Updates Drug Administration Law to Capture Recent

Read the full 744 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers